How ARIZ Precision Medicine is Transforming Cancer Treatment – with Brad Niles

Join host Josh David Miller (JDM) as he sits down with Brad Niles, Co-founder and CEO of ARIZ Precision Medicine, a biotech company developing RNA interference (RNAi)-based treatments to target the genetic drivers of cancer.

Brad shares how his personal experiences with cancer inspired him to innovate new therapies, leading to the launch of ARIZ. They explore the journey of taking a deep-tech startup from idea to clinical trials, the capital-intensive nature of biotech, and how precision medicine is changing the future of oncology.

They also discuss:

• 🔬 How RNA interference (RNAi) technology is transforming cancer treatment
• 💡 The challenges of drug discovery and bringing a therapy from preclinical research to human trials
• 💰 The funding strategies for deep-tech startups, including raising a Series A and securing partnerships
• 🤝 The role of big pharma collaborations in advancing novel cancer therapies
• 🎯 Why targeting the genetic drivers of cancer instead of organ-specific tumors could be a game-changer

For anyone interested in biotech startups, precision medicine, or the future of cancer treatment, this episode is a must-listen!

Connect with ARIZ Precision Medicine & Brad Niles

• 🌐 ARIZBio.com \ 🔗 LinkedIn - ARIZ Precision Medicine \ 🔗 LinkedIn - Brad Niles
• 
  

For more information and insights into entrepreneurship in Sacramento, be sure to visit StartupSac.com.

Hosted on Acast. See acast.com/privacy for more information.